Considerations for an In Vitro, Cell-Based Testing Platform for Detection of Adverse Drug-Induced Inotropic Effects in Early Drug Development. Part 1: General Considerations for Development of Novel Testing Platforms.
Saved in:
| Title: | Considerations for an In Vitro, Cell-Based Testing Platform for Detection of Adverse Drug-Induced Inotropic Effects in Early Drug Development. Part 1: General Considerations for Development of Novel Testing Platforms. |
|---|---|
| Authors: | Guth BD; Department of Drug Discovery Sciences, Boehringer Ingelheim Pharma GmbH & Co KG, Biberach an der Riss, Germany.; PreClinical Drug Development Platform (PCDDP), North-West University, Potchefstroom, South Africa., Engwall M; Safety Pharmacology and Animal Research Center, Amgen Research, Thousand Oaks, CA, United States., Eldridge S; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States., Foley CM; Department of Integrative Pharmacology, Integrated Sciences and Technology, AbbVie, North Chicago, IL, United States., Guo L; Laboratory of Investigative Toxicology, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD, United States., Gintant G; Department of Integrative Pharmacology, Integrated Sciences and Technology, AbbVie, North Chicago, IL, United States., Koerner J; Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, United States., Parish ST; Health and Environmental Sciences Institute, Washington, DC, United States., Pierson JB; Health and Environmental Sciences Institute, Washington, DC, United States., Ribeiro AJS; Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translation Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, United States., Zabka T; Department of Safety Assessment, Genentech, South San Francisco, CA, United States., Chaudhary KW; Global Safety Pharmacology, GlaxoSmithKline plc, Collegeville, PA, United States., Kanda Y; Division of Pharmacology, National Institute of Health Sciences, Kanagawa, Japan., Berridge B; National Toxicology Program, National Institute of Environmental Health Sciences, Durham, NC, United States. |
| Source: | Frontiers in pharmacology [Front Pharmacol] 2019 Aug 09; Vol. 10, pp. 884. Date of Electronic Publication: 2019 Aug 09 (Print Publication: 2019). |
| Publication Type: | Journal Article; Review |
| Journal Info: | Publisher: Frontiers Media] Country of Publication: Switzerland NLM ID: 101548923 Publication Model: eCollection Cited Medium: Print ISSN: 1663-9812 (Print) Linking ISSN: 16639812 NLM ISO Abbreviation: Front Pharmacol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1663-9812 |
|---|---|
| DOI: | 10.3389/fphar.2019.00884 |
